{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:32Z","timestamp":1787020232020,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011758","name":"Ministrstvo za visoko \u0161olstvo, znanost in tehnologijo","doi-asserted-by":"publisher","award":["P3-0289(C)"],"award-info":[{"award-number":["P3-0289(C)"]}],"id":[{"id":"10.13039\/501100011758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5535-2","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T07:03:06Z","timestamp":1554188586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1\/2 genes in patients with tubo-ovarian high grade serous carcinoma"],"prefix":"10.1186","volume":"19","author":[{"given":"Andreja","family":"Gornjec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdjan","family":"Novakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Stegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Hocevar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziva","family":"Pohar Marinsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gazic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateja","family":"Krajc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Skof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"5535_CR1","first-page":"1125","volume-title":"Contribution Of Brca1 Mutations To Ovarian Cancer","author":"JF Stratton","year":"1997","unstructured":"Stratton JF. Contribution Of Brca1 Mutations To Ovarian Cancer; 1997. p. 1125\u201330."},{"key":"5535_CR2","volume-title":"BRCA1 and BRCA2 Mutations Account for a Large","author":"T Pal","year":"2005","unstructured":"Pal T, Permuth-wey J, Betts JA, Krischer JP, Ph D, Fiorica J, et al. BRCA1 and BRCA2 Mutations Account for a Large. 2005."},{"issue":"2","key":"5535_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","volume":"121","author":"S Zhang","year":"2011","unstructured":"Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol [Internet]. 2011;121(2):353\u20137 Available from: \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2011.01.020\n                    \n                  .","journal-title":"Gynecol Oncol [Internet]"},{"key":"5535_CR4","doi-asserted-by":"crossref","unstructured":"Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci [Internet. 2011;108(44):18032\u20137 Available from: \n                    https:\/\/www.pnas.org\/content\/pnas\/early\/2011\/10\/13\/1115052108.full.pdf\n                    \n                  .","DOI":"10.1073\/pnas.1115052108"},{"issue":"1","key":"5535_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3892-2","volume":"18","author":"C Page Le","year":"2018","unstructured":"Le Page C, Rahimi K, K\u00f6bel M, Tonin PN, Meunier L, Portelance L, et al. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer. 2018;18(1):1\u201318.","journal-title":"BMC Cancer"},{"issue":"3","key":"5535_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian Cancer. Am J Hum Genet [Internet]. 2001;68(3):700\u201310 Available from: \n                    https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0002929707631097\n                    \n                  .","journal-title":"Am J Hum Genet [Internet]"},{"issue":"21","key":"5535_CR7","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol. 2012;30(21):2654\u201363.","journal-title":"J Clin Oncol"},{"issue":"7353","key":"5535_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"The Cancer Genome Atlas Network","year":"2011","unstructured":"The Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature."},{"issue":"3","key":"5535_CR9","first-page":"764","volume":"20","author":"KP Pennington","year":"2015","unstructured":"Pennington KP, Walsh T, Harrell MI, Lee MK, Christopher C, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian. Fallopian Tube, and Peritoneal Carcinomas. 2015;20(3):764\u201375.","journal-title":"Fallopian Tube, and Peritoneal Carcinomas"},{"issue":"3","key":"5535_CR10","doi-asserted-by":"publisher","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","volume":"217","author":"M Petrillo","year":"2017","unstructured":"Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol [Internet]. 2017;217(3):334.e1\u20139 Available from: \n                    https:\/\/doi.org\/10.1016\/j.ajog.2017.05.036\n                    \n                  .","journal-title":"Am J Obstet Gynecol [Internet]"},{"key":"5535_CR11","doi-asserted-by":"publisher","unstructured":"Weren RDA, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, et al. Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for. Genetic. 2017;38(2):226-35. \n                    https:\/\/doi.org\/10.1002\/humu.23137\n                    \n                  . Epub 2016 Nov 9.","DOI":"10.1002\/humu.23137"},{"issue":"11","key":"5535_CR12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol [Internet]. 2016;17(11):1579\u201389 Available from: \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30376-X\n                    \n                  .","journal-title":"Lancet Oncol [Internet]."},{"issue":"4","key":"5535_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","volume":"307","author":"KL Bolton","year":"2012","unstructured":"Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Ben\u00edtez J, Garc\u00eda MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godw PPE kConFab ICGARN. Association Between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer. Jama. 2012;307(4):382\u201390.","journal-title":"Jama"},{"issue":"8","key":"5535_CR14","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol [Internet]. 2014;15(8):852\u201361 Available from: \n                    https:\/\/doi.org\/10.1016\/S1470-2045(14)70228-1\n                    \n                  .","journal-title":"Lancet Oncol [Internet]"},{"key":"5535_CR15","doi-asserted-by":"crossref","unstructured":"Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Sun J, Yelensky R, et al. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high- grade serous ovarian cancers in the maintenance setting. 2017;8(27):43653\u201343661.","DOI":"10.18632\/oncotarget.17613"},{"issue":"4","key":"5535_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/path.4105","volume":"229","author":"M Castellarin","year":"2013","unstructured":"Castellarin M, Milne K, Zeng T, Tse K, Mayo M, Zhao Y, et al. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J Pathol. 2013;229(4):515\u201324.","journal-title":"J Pathol"},{"issue":"22","key":"5535_CR17","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","volume":"29","author":"B Norquist","year":"2011","unstructured":"Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29(22):3008\u201315.","journal-title":"J Clin Oncol"},{"issue":"5","key":"5535_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/cncy.21522","volume":"123","author":"RH Shah","year":"2015","unstructured":"Shah RH, Scott SN, MPH BAR, Levine DA, Lin O, et al. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma. Cancer Cythopathol. 2015;123(5):289\u201397.","journal-title":"Cancer Cythopathol"},{"issue":"1","key":"5535_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/path.4230","volume":"231","author":"A Bashashati","year":"2013","unstructured":"Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013;231(1):21\u201334.","journal-title":"J Pathol"},{"key":"5535_CR20","doi-asserted-by":"crossref","unstructured":"Hoogstraat M, Pagter MS De, Cirkel GA, Roosmalen MJ Van, Harkins TT, Duran K, et al. Genomic and transcriptomic plasticity in treatment naive ovarian cancer. 2014;200\u2013211.","DOI":"10.1101\/gr.161026.113"},{"key":"5535_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.11.005","volume":"24","author":"NG Alkema","year":"2016","unstructured":"Alkema NG, Wisman GBA, Van Der Zee AGJ, Van Vugt MATM, De Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resist Updat [Internet]. 2016;24:55\u201369 Available from: \n                    https:\/\/doi.org\/10.1016\/j.drup.2015.11.005\n                    \n                  .","journal-title":"Drug Resist Updat [Internet]"},{"issue":"1","key":"5535_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/path.4819","volume":"241","author":"YJ Choi","year":"2017","unstructured":"Choi YJ, Rhee JK, Hur SY, Kim MS, Lee SH, Chung YJ, et al. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling. J Pathol. 2017;241(1):57\u201366.","journal-title":"J Pathol"},{"issue":"suppl_8","key":"5535_CR23","doi-asserted-by":"publisher","first-page":"viii46","DOI":"10.1093\/annonc\/mdx452","volume":"28","author":"JA Ledermann","year":"2017","unstructured":"Ledermann JA. Front-line therapy of advanced ovarian cancer: new approaches. Ann Oncol [Internet]. 2017;28(suppl_8):viii46\u201350 Available from: \n                    https:\/\/academic.oup.com\/annonc\/article\/28\/suppl_8\/viii46\/4693818\n                    \n                  .","journal-title":"Ann Oncol [Internet]"},{"key":"5535_CR24","doi-asserted-by":"crossref","unstructured":"Adank, M. A., Brogi E BF et al. Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded ( FFPE ) tissue. 2006;337\u2013342.","DOI":"10.1007\/s10689-006-0003-y"},{"issue":"2","key":"5535_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ab.2009.08.016","volume":"395","author":"J Lin","year":"2009","unstructured":"Lin J, Kennedy SH, Svarovsky T, Rogers J, Kemnitz JW, Xu A, et al. High-quality genomic DNA extraction from formalin-fixed and paraffin-embedded samples deparaffinized using mineral oil. Anal Biochem [Internet]. 2009;395(2):265\u20137 Available from: \n                    https:\/\/doi.org\/10.1016\/j.ab.2009.08.016\n                    \n                  .","journal-title":"Anal Biochem [Internet]"},{"key":"5535_CR26","doi-asserted-by":"publisher","unstructured":"Capoluongo E, Ellison G, L\u00f3pez-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, et al. Guidance statement on BRCA1\/2 tumor testing in ovarian Cancer patients. Semin Oncol [Internet. 2017;44(3):187\u201397 Available from: \n                    https:\/\/doi.org\/10.1053\/j.seminoncol.2017.08.004\n                    \n                  .","DOI":"10.1053\/j.seminoncol.2017.08.004"},{"issue":"11","key":"5535_CR27","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282\u201391.","journal-title":"Hum Mutat"},{"issue":"5","key":"5535_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"KD Laboratories","year":"2015","unstructured":"Laboratories KD, Genetics M, Health O, Road P, Molecular C, Children N, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"key":"5535_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/acprof:oso\/9780195315493.003.0002","volume-title":"Determining sample size","author":"P Dattalo","year":"2008","unstructured":"Dattalo P. In: Tony Tripodi PE, editor. Determining sample size. New York: Oxford University Press; 2008. p. 11\u201355."},{"issue":"2","key":"5535_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1101\/gr.161026.113","volume":"24","author":"M Hoogstraat","year":"2014","unstructured":"Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen MJ, Harkins TT, Duran K, et al. Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res [Internet]. 2014;24(2):200\u201311 Available from: \n                    https:\/\/genome.cshlp.org\/content\/early\/2013\/11\/05\/gr.161026.113\n                    \n                  .","journal-title":"Genome Res [Internet]"},{"issue":"2","key":"5535_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1515\/raon-2017-0013","volume":"51","author":"M Cvelbar","year":"2017","unstructured":"Cvelbar M, Hocevar M, Novakovic S, Stegel V, Perhavec A, Krajc M. Genetic counselling, BRCA1\/2 status and clinico-pathologic characteristics of patients with ovarian cancer before 50 years of age. Radiol Oncol. 2017;51(2):187\u201394.","journal-title":"Radiol Oncol"},{"issue":"6","key":"5535_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/jnci\/94.1.61","volume":"94","author":"JP Geisler","year":"2002","unstructured":"Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst. 2002;94(6):61\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"5535_CR33","unstructured":"Clinical N, Guidelines P, Guidelines N. Genetic\/Familial High-Risk Assessment : Breast and Ovarian 2018;"},{"issue":"6","key":"5535_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells","year":"2015","unstructured":"Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid [Internet]. 2015;25(6):567\u2013610 Available from: \n                    https:\/\/www.liebertpub.com\/doi\/10.1089\/thy.2014.0335\n                    \n                  .","journal-title":"Thyroid [Internet]"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5535-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5535-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5535-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T19:09:16Z","timestamp":1585681756000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5535-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5535"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5535-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"10 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"296"}}